{"name":"Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes","slug":"instituto-nacional-de-perinatologia-isidro-espinosa-de-los-reyes","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Orally Colostrum","genericName":"Orally Colostrum","slug":"orally-colostrum","indication":"Immune support and gastrointestinal health (Phase 3 indication not fully specified in available data)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"medical nutrition therapy + metformin","genericName":"medical nutrition therapy + metformin","slug":"medical-nutrition-therapy-metformin","indication":"Gestational diabetes mellitus (likely, given Instituto Nacional de Perinatologia focus)","status":"marketed"}]}],"pipeline":[{"name":"Orally Colostrum","genericName":"Orally Colostrum","slug":"orally-colostrum","phase":"phase_3","mechanism":"Oral colostrum provides passive immunological and nutritional support through bioactive compounds including immunoglobulins, lactoferrin, and growth factors.","indications":["Immune support and gastrointestinal health (Phase 3 indication not fully specified in available data)"],"catalyst":""},{"name":"medical nutrition therapy + metformin","genericName":"medical nutrition therapy + metformin","slug":"medical-nutrition-therapy-metformin","phase":"marketed","mechanism":"Medical nutrition therapy combined with metformin reduces blood glucose through dietary management and insulin sensitization, respectively.","indications":["Gestational diabetes mellitus (likely, given Instituto Nacional de Perinatologia focus)","Type 2 diabetes management"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE10cmRRZkF1UG92WUhOYnNHZ0FBOGo3WnZleEQzWk9HOUVYNk1naUVySDh0MlRCWjFqdGhLN09YckhCb19MbXFjUlZqM25uZ1VUZHliSVB6SVlUTm5JUTJza1JUZTA5U253U1dZdg?oc=5","date":"2023-12-08","type":"pipeline","source":"SCIRP Open Access","summary":"Evaluation of the Influence of Hyoscine Butylbromide on the Oral Bioavailability of Lansoprazole in Healthy Adult Volunteers - SCIRP Open Access","headline":"Evaluation of the Influence of Hyoscine Butylbromide on the Oral Bioavailability of Lansoprazole in Healthy Adult Volunt","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}